Stay updated with breaking news from F Ejection Fraction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In patients who had revascularization after an acute MI and had a preserved EF, long-term beta-blocker use showed no benefit compared with no beta-blockers, in REDUCE-AMI.
For an all-comer population with any impairment of LV function, an interarterial shunt device missed the primary endpoint in RELIEVE-HF, but benefit was seen with LVEF less than 40%.
A new study suggested indexed left ventricular systolic volume may predict benefit of beta blocker withdrawal in patients with heart failure with preserved ejection fraction.
Preliminary results of the pivotal phase 3 trial show benefit of the cardiac myosin inhibitor, aficamten, in obstructive hypertrophic cardiomyopathy.
The Barostim neuromodulation system is now indicated in NYHA class III or class II HF despite guideline-directed medical therapies, with LVEF ≤ 35% and NT-proBNP < 1600 pg/mL.